Specificity and regulation of extracellularly regulated kinase1/2 phosphorylation through corticotropin-releasing factor (CRF) receptors 1 and 2β by the CRF/urocortin family of peptides

被引:86
作者
Brar, BK [1 ]
Chen, A [1 ]
Perrin, MH [1 ]
Vale, W [1 ]
机构
[1] Salk Inst Biol Studies, Clayton Fdn Labs Peptide Biol, La Jolla, CA 92037 USA
关键词
D O I
10.1210/en.2003-1023
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Corticotropin-releasing factor (CRF) receptor (CRFR)-mediated activation of the ERKs 1/2-p42 and -44) has been reported for CRF, urocortin ( Ucn)-I, and sauvagine. Recently two new members of the CRF/Ucn family of peptides have been identified, Ucn-II/stresscopin-related peptide and Ucn-III/stress-copin. Using Chinese hamster ovary cells stably expressing CRFR1 and CRFR2beta, we show that Ucn-I, Ucn-II and Ucn-III activate ERK1/2-p42, 44 via CRFR2beta. CRF and Ucn-I but not Ucn-II or Ucn-III activates ERK1/2-p42, 44 in Chinese hamster ovary cells stably expressing CRFR1. The selectivity of the ligands for CRFR1 and CRFR2beta is shown in a time- and dose-dependent manner. The regulatory mechanisms for ERK1/2p42, 44 activation by both receptor types are dependent on phosphatidylinositol-3 OH kinase, MAPK kinase 1, and phospholipase C. Raf-1 kinase, tyrosine kinases, and possibly intracellular Ca2+ provide regulatory roles for Ucn-I activation of ERK1/2-p42, 44 by CRFR1 and CRFR2beta. Studies of the regulation of ERK1/2-p42, 44 by Ucn-I were extended to cell lines that endogenously express CRFR1 (AtT-20 and CATHa cells) and CRFR2 (A7r5 and CATHa cells). Use of the G(i) and G(o) protein inhibitor pertussis toxin showed that ERK1/2-p42, 44 activation by Ucn-I via CRFR1 and CRFR2beta are both G(i) and/or G(o) protein dependent. Based on the data in this study, we present putative signaling pathways by which the CRF/Ucn family of peptides activate ERK1/2-p42, 44 by CRFRs.
引用
收藏
页码:1718 / 1729
页数:12
相关论文
共 52 条
[41]   Potent and long-acting corticotropin releasing factor (CRF) receptor 2 selective peptide competitive antagonists [J].
Rivier, J ;
Gulyas, J ;
Kirby, D ;
Low, W ;
Perrin, MH ;
Kunitake, K ;
DiGruccio, M ;
Vaughan, J ;
Reubi, JC ;
Waser, B ;
Koerber, SC ;
Martinez, V ;
Wang, L ;
Taché, Y ;
Vale, W .
JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (21) :4737-4747
[42]   Corticotropin-releasing factor type 1 and type 2α receptors regulate phosphorylation of calcium/cyclic adenosine 3′,5′-monophosphate response element-binding protein and activation of p42/p44 mitogen-activated protein kinase [J].
Rossant, CJ ;
Pinnock, RD ;
Hughes, J ;
Hall, MD ;
McNulty, S .
ENDOCRINOLOGY, 1999, 140 (04) :1525-1536
[43]   Development of anticancer drugs targeting the MAP kinase pathway [J].
Sebolt-Leopold, JS .
ONCOGENE, 2000, 19 (56) :6594-6599
[44]   Cutaneous expression of corticotropin-releasing hormone (CRH), urocortin, and CRH receptors [J].
Slominski, A ;
Wortsman, J ;
Pisarchik, A ;
Zbytek, B ;
Linton, EA ;
Mazurkiewicz, JE ;
Wei, ET .
FASEB JOURNAL, 2001, 15 (10) :1678-1693
[45]   IDENTIFICATION OF A NOVEL MURINE RECEPTOR FOR CORTICOTROPIN-RELEASING HORMONE EXPRESSED IN THE HEART [J].
STENZEL, P ;
KESTERSON, R ;
YEUNG, W ;
CONE, RD ;
RITTENBERG, MB ;
STENZELPOORE, MP .
MOLECULAR ENDOCRINOLOGY, 1995, 9 (05) :637-645
[46]  
SURI C, 1993, J NEUROSCI, V13, P1280
[47]   CHARACTERIZATION OF A 41-RESIDUE OVINE HYPOTHALAMIC PEPTIDE THAT STIMULATES SECRETION OF CORTICOTROPIN AND BETA-ENDORPHIN [J].
VALE, W ;
SPIESS, J ;
RIVIER, C ;
RIVIER, J .
SCIENCE, 1981, 213 (4514) :1394-1397
[48]   UROCORTIN, A MAMMALIAN NEUROPEPTIDE RELATED TO FISH UROTENSIN-I AND TO CORTICOTROPIN-RELEASING FACTOR [J].
VAUGHAN, J ;
DONALDSON, C ;
BITTENCOURT, J ;
PERRIN, MH ;
LEWIS, K ;
SUTTON, S ;
CHAN, R ;
TURNBULL, AV ;
LOVEJOY, D ;
RIVIER, C ;
RIVIER, J ;
SAWCHENKO, PE ;
VALE, W .
NATURE, 1995, 378 (6554) :287-292
[49]  
VITA N, 1993, FEBS LETT, V355, P1
[50]  
WAGNER U, 1985, GRUPPENDYNAMIK, V16, P5